EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pilot-Scale Downstream Processing of Recombinant Influenza Virus Vectors Expressing Brucella spp. Antigens Using an Integrated Membrane-Chromatography Purification Platform

Nurika Assanzhanova iD, Aigerim Sagymbayeva iD, Gaukhar Shynybekova iD, Kamshat Shorayeva iD, Sholpan Ryskeldinova iD, Aigerim Mailybayeva iD, Yeldos Myrzakhmetov iD, Ekaterina Yamanova iD, Rassul Sidikhov iD, Meiyrim Almezhanova iD, Samat Zhaksylyk iD, Zharkynai Absatova iD und 3 weitere

Vaccines · 17.07.2026 · 14 (7) · 626

DOI: 10.3390/vaccines14070626 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 17.07.2026. Verfasst von Nurika Assanzhanova und 14 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Biological Safety Problems, National Holding "QazBioPharm", Gvardeiskiy 080409, Kazakhstan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of the Republic of Kazakhstan, Limited Liability Partnership Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Brucellosis remains a significant zoonotic infection affecting approximately 500,000 people worldwide annually, with no licensed human vaccine available. Recombinant influenza virus vectors expressing Brucella spp. antigens represent a promising vaccine platform. However, transitioning from laboratory constructs to clinical candidates requires validation of scalable purification methods compliant with Good Manufacturing Practice (GMP) standards. This study aimed to develop and optimize a pilot-scale purification protocol for these vectors.

Methods

Recombinant influenza A viruses (H5N1) expressing Brucella spp. antigens (Omp16, Omp19, L7/L12, Cu-Zn SOD) were propagated in MDCK cell culture. The optimized purification process included: (1) clarification; (2) ultrafiltration/diafiltration (100 kDa MWCO); (3) two-step chromatography (anion-exchange Q-Sepharose® Fast Flow and multimodal Capto™ Core 700); and (4) sterile filtration. Process validation was performed across three independent pilot-scale batches (20 L each).

Results

The purification process demonstrated high reproducibility for all constructs. Final preparations met established quality criteria: infectious titer ≥ 5.2 log10 TCID50/mL, hemagglutination activity 7.33 ± 0.58–8.33 ± 0.58 log2, total protein content 157–305 μg/mL, residual host cell DNA < 10 ng/dose, and bacterial endotoxin levels ≤ 0.15 IU/mL. The overall recovery of infectious virus was 20–24%, an optimal value for multi-stage bioprocessing. Preservation of the target genetic insert was confirmed in all final preparations by PCR and sequencing.

Conclusions

The developed integrated purification protocol yields vectors with high purification efficiency, preserving biological activity and meeting regulatory quality requirements for residual host cell DNA and endotoxins. The technological platform demonstrated versatility, robustness (inter-batch coefficient of variation for yield did not exceed 10–12%), and scalability, establishing a foundation for preclinical and clinical studies of candidate brucellosis vaccines.

Schlagwörter

Stichwörter der Autor:innen

Brucellabrucellosisinfluenza virusion-exchange chromatographyrecombinant vaccinetangential flow filtrationviral vectorvirus purification

Autor:innen und Institutionen

  • Research Institute for Biological Safety Problems, National Holding "QazBioPharm", Gvardeiskiy 080409, Kazakhstan.

ORCID-Profile: Nurika Assanzhanova, Aigerim Sagymbayeva, Gaukhar Shynybekova, Kamshat Shorayeva, Sholpan Ryskeldinova, Aigerim Mailybayeva, Yeldos Myrzakhmetov, Ekaterina Yamanova, Rassul Sidikhov, Meiyrim Almezhanova, Samat Zhaksylyk, Zharkynai Absatova, Kuandyk Zhugunissov, Olga Chervyakova, Nurlan Akmyrzayev

Förderung

  • Ministry of Health of the Republic of Kazakhstan
  • Limited Liability Partnership Research Institute

Zitieren

APA

Assanzhanova, N., Sagymbayeva, A., Shynybekova, G., Shorayeva, K., Ryskeldinova, S., Mailybayeva, A., Myrzakhmetov, Y., Yamanova, E., Sidikhov, R., Almezhanova, M., Zhaksylyk, S., Absatova, Z., Zhugunissov, K., Chervyakova, O., & Akmyrzayev, N. (2026). Pilot-Scale Downstream Processing of Recombinant Influenza Virus Vectors Expressing Brucella spp. Antigens Using an Integrated Membrane-Chromatography Purification Platform. Vaccines, 14(7), 626. https://doi.org/10.3390/vaccines14070626

Vancouver

Assanzhanova N, Sagymbayeva A, Shynybekova G, Shorayeva K, Ryskeldinova S, Mailybayeva A, et al. Pilot-Scale Downstream Processing of Recombinant Influenza Virus Vectors Expressing Brucella spp. Antigens Using an Integrated Membrane-Chromatography Purification Platform. Vaccines. 2026;14(7):626. doi:10.3390/vaccines14070626

BibTeX
@article{Assanzhanova2026,
  author = {Assanzhanova, Nurika and Sagymbayeva, Aigerim and Shynybekova, Gaukhar and Shorayeva, Kamshat and Ryskeldinova, Sholpan and Mailybayeva, Aigerim and Myrzakhmetov, Yeldos and Yamanova, Ekaterina and Sidikhov, Rassul and Almezhanova, Meiyrim and Zhaksylyk, Samat and Absatova, Zharkynai and Zhugunissov, Kuandyk and Chervyakova, Olga and Akmyrzayev, Nurlan},
  title = {Pilot-Scale Downstream Processing of Recombinant Influenza Virus Vectors Expressing Brucella spp. Antigens Using an Integrated Membrane-Chromatography Purification Platform},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {7},
  pages = {626},
  doi = {10.3390/vaccines14070626}
}
Kostenlos starten →